Portal de Periódicos da CAPES

Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine

2014; Elsevier BV; Volume: 441; Linguagem: Inglês

10.1016/j.cca.2014.12.023

1873-3492

Madoka Yoshida, Kyohei Higashi, Kyoshiro Kuni, Mutsumi Mizoi, Ryotaro Saiki, Mizuho Nakamura, Masaaki Waragai, Kenichi Uemura, Toshihiko Toida, Keiko Kashiwagi, Kazuei Igarashi,

Muscle metabolism and nutrition

We previously reported that the level of urinary 3-hydroxypropyl mercapturic acid (3-HPMA)/creatinine (Cre) was reduced following stroke. The aim of this study was to determine whether the level of 3-HPMA/Cre in urine was reduced in subjects with dementia. The level of 3-HPMA was measured by LC–MS/MS, and that of amino acid conjugated acrolein (AC-Acro) was by ELISA. The study included 128 elderly subjects divided into 74 non-demented (control), 22 mild cognitive impairment (MCI) and 32 Alzheimer's disease (AD) subjects. The urinary 3-HPMA/Cre and AC-Acro/Cre in MCI plus AD subjects were significantly lower than those in control subjects. In addition, urinary Cre in AD subjects was significantly higher than that in MCI subjects, and 3-HPMA/Cre and AC-Acro/Cre in AD subjects were significantly lower than that in MCI subjects. Among these three markers, the lower 3-HPMA/Cre ratio was most strongly correlated with the decline of MMSE (Mini-Mental State Examination) and the increase in CDRsob (Clinical Dementia Rating Scale Sum of Boxes Scores). Furthermore, reduction in 3-HPMA/Cre in urine was well correlated with increase in Aβ40/42 in plasma in demented subjects. The results indicate that 3-HPMA/Cre in urine is the most reliable biochemical marker to distinguish AD subjects from MCI subjects among three markers.